{
    "clinical_study": {
        "@rank": "121263", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I. Determine the safety and efficacy of azacitidine and phenylbutyrate in treatment of\n      patients with thalassemia major."
        }, 
        "brief_title": "Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major", 
        "condition": "Thalassemia Major", 
        "condition_browse": {
            "mesh_term": [
                "Beta-Thalassemia", 
                "Thalassemia"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients receive azacitidine IV continuously on days 1-4 and oral\n      phenylbutyrate three times a day on days 14-42. Bone marrow needle aspiration is performed\n      on days 6, 14, and 42 to assess disease response to treatment. If no response on day 42, a\n      second course of azacitidine and phenylbutyrate begins 7 days later.\n\n      Patients are followed weekly for 3 months and then monthly thereafter."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n        Diagnosis of thalassemia major Progressive disease defined as: Increasing transfusion\n        requirement or difficulty in maintenance of hemoglobin levels greater than 7 g/dL as a\n        consequence of autologous or allogeneic antibodies OR Increasing extramedullary\n        hematopoiesis causing compression phenomena OR Disease with complications of iron overload\n        despite traditional transfusion and iron chelation therapy (e.g., heart failure, decreased\n        cardiac ejection fraction, endocrinopathy, or evidence of progressive liver dysfunction)\n\n        Standard transfusion therapy or iron chelation therapy must be contraindicated\n\n        --Prior/Concurrent Therapy--\n\n        See Disease Characteristics\n\n        --Patient Characteristics--\n\n        Performance status: ECOG 0-2\n\n        Life expectancy: Greater than 10 days Not moribund\n\n        Hematopoietic: See Disease Characteristics\n\n        Hepatic: See Disease Characteristics AST or ALT no greater than 3 times upper limit of\n        normal (ULN) Bilirubin no greater than 1.5 times ULN (unless due to hemolysis or Gilbert's\n        disease) Albumin at least 3 g/dL No severe concurrent hepatic disease\n\n        Renal: Creatinine no greater than 2 mg/dL Creatinine clearance at least 60 mL/min No\n        severe concurrent renal disease\n\n        Cardiovascular: See Disease Characteristics No New York Heart Association class III or IV\n\n        Other: Not pregnant or nursing No severe concurrent metabolic disease No severe sepsis or\n        septic shock No concurrent altered mental status or seizure disorder No concurrent\n        myelodysplastic syndrome or leukemia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "24", 
        "firstreceived_date": "December 6, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00007072", 
            "org_study_id": "199/15578", 
            "secondary_id": [
                "NIDDK-00-DK-0166", 
                "NCI-1311"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "azacitidine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "phenylbutyrate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Azacitidine", 
                "4-phenylbutyric acid"
            ]
        }, 
        "keyword": [
            "genetic diseases and dysmorphic syndromes", 
            "hematologic disorders", 
            "rare disease", 
            "thalassemia major"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bethesda", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "20892"
                }, 
                "name": "Clinical Hematology Branch"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
            "last_name": "Griffin Platt Rodgers", 
            "role": "Study Chair"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00007072"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "November 2000", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2003"
    }, 
    "geocoordinates": {
        "Clinical Hematology Branch": "38.985 -77.095"
    }
}